Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

FDA Tepid on Amylyx’s Second Try for ALS Therapy AMX0035

  • Post author:PacConAdmin
  • Post published:September 6, 2022
  • Post category:Drug Industry Daily

The FDA isn’t impressed by the data Amylyx Pharmaceuticals is relying on in its second attempt to get the nod for AMX0035, its investigational amyotrophic lateral sclerosis (ALS) therapy. Source:…

Continue ReadingFDA Tepid on Amylyx’s Second Try for ALS Therapy AMX0035

Analgesic Manufacturer Skyless Hit With 483 for Absence of GMP Procedures, Training

  • Post author:PacConAdmin
  • Post published:September 6, 2022
  • Post category:Drug Industry Daily

Puerto Rico-based drug manufacturer Skyless was slapped with a five-observation 483 from the FDA that centered on the plant’s lack of any manufacturing procedures and training for employees. Source: Drug…

Continue ReadingAnalgesic Manufacturer Skyless Hit With 483 for Absence of GMP Procedures, Training

Inspection Findings at Reykjavik Facility Delay Alvotech’s BLA Approval

  • Post author:PacConAdmin
  • Post published:September 6, 2022
  • Post category:Drug Industry Daily

The FDA has informed Icelandic biosimilars developer Alvotech that it must address issues found in the March 2022 preapproval inspection of the company’s Reykjavik manufacturing facility before the agency will…

Continue ReadingInspection Findings at Reykjavik Facility Delay Alvotech’s BLA Approval

Bayer to Settle for $40M in Suits Alleging Kickbacks and False Statements

  • Post author:PacConAdmin
  • Post published:September 6, 2022
  • Post category:Drug Industry Daily

Bayer has agreed to pay $40 million to resolve alleged violations of the False Claims Act (FCA) in connection with three of the company’s drugs, the U.S. Department of Justice…

Continue ReadingBayer to Settle for $40M in Suits Alleging Kickbacks and False Statements

Otsuka and H. Lundbeck Sue Viatris Over Abilify Maintena Again

  • Post author:PacConAdmin
  • Post published:September 2, 2022
  • Post category:Drug Industry Daily

Otsuka Holdings and H. Lundbeck filed another lawsuit in an attempt to stop Viatris (formerly Mylan) from marketing a generic of the injectable version of the antipsychotic drug Abilify Maintena…

Continue ReadingOtsuka and H. Lundbeck Sue Viatris Over Abilify Maintena Again

Drug-free Topical Gel Could Become U.S.’ First OTC Erectile Dysfunction Treatment

  • Post author:PacConAdmin
  • Post published:September 2, 2022
  • Post category:Drug Industry Daily

Futura Medical’s MED3000, a drug-free topical gel for treating erectile dysfunction (ED), stood up well against Cialis (tadalafil) in a phase 3 study that could ultimately lead to the first…

Continue ReadingDrug-free Topical Gel Could Become U.S.’ First OTC Erectile Dysfunction Treatment

Potential Product Contamination, Lack of Records Lands BPI Labs a Form 483

  • Post author:PacConAdmin
  • Post published:September 2, 2022
  • Post category:Drug Industry Daily

During an inspection of BPI Labs in Evanston, Wyo., the FDA’s investigator found multiple issues with production and quality control records, as well as areas of potential product contamination. Source:…

Continue ReadingPotential Product Contamination, Lack of Records Lands BPI Labs a Form 483

United Therapeutics Wins One, Loses One in Tyvaso Patent Dispute

  • Post author:PacConAdmin
  • Post published:September 2, 2022
  • Post category:Drug Industry Daily

A U.S. District Court in Delaware has decided in favor of United Therapeutics over Liquidia in one of its patent disputes over Tyvaso (treprostinil), a drug used to treat pulmonary…

Continue ReadingUnited Therapeutics Wins One, Loses One in Tyvaso Patent Dispute

District Judge Says FDA Doesn’t Have Oversight Over Stem Cell Therapy

  • Post author:PacConAdmin
  • Post published:September 1, 2022
  • Post category:Drug Industry Daily

A federal judge ruled earlier this week that stem cell therapies are procedures, not drugs, and that the FDA has no jurisdiction over them, blocking the agency’s attempt to regulate…

Continue ReadingDistrict Judge Says FDA Doesn’t Have Oversight Over Stem Cell Therapy

Novo Nordisk Snags Forma’s Sickle Cell Candidate in $1.1 Million Deal

  • Post author:PacConAdmin
  • Post published:September 1, 2022
  • Post category:Drug Industry Daily

Novo Nordisk is beefing up its hematologic portfolio with the $1.1 billion acquisition of Forma Therapeutics, snagging the company’s late-stage sickle cell anemia candidate etavopivat. Source: Drug Industry Daily

Continue ReadingNovo Nordisk Snags Forma’s Sickle Cell Candidate in $1.1 Million Deal
  • Go to the previous page
  • 1
  • …
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.